Mumbai: Two lakh Indian households are using GLP-1 drugs like Ozempic and Mounjaro to keep diabetes or obesity in check, a consultancy firm said on Tuesday.
To advertise here,
Estimating the overall market size for such products is very difficult because the number of households consuming them is doubling every year, Ravi Kapoor, partner and leader for the retail and consumer sector at PwC, said.
“2 lakh households are using GLP-1 drugs. Many of them are concentrated in the top five or six metros,” Kapoor told reporters here.
Each of these households spends between Rs 8,000-16,000 a month for buying the drugs, which have to be bought on prescription, he said, adding that there are about 20 brands of drugs available in the country.
He said the usage data is accounted for by households because many a time both a husband and wife may be using the drugs. Given the high prevalence of diabetes and lifestyle-oriented cardiovascular disorders, the potential market in the country for GLP-1 drugs is huge, he added.
Meanwhile, PWC launched a survey report, which pointed to an overwhelming number of the 1,005 respondents seeking to prioritize well-being but being constrained by barriers to follow a healthy lifestyle.
The survey, conducted in January and February, said that 97 percent of the respondents wish to prioritize long-term well-being, but 67 percent identify stress, fatigue, or low energy as barriers to following a healthy everyday wellness routine.
Kapoor said barriers may include factors such as traffic, nuclear families and commitment to children.
The survey findings, which were released amid a heightened focus on food safety in the country, also revealed that Indians are more concerned about factors such as microplastics than the global average from the survey.
Similarly, Indian consumers are also more concerned about protein intake, fiber content in food and calories consumed than the global average, it said.
(Except for the headline, this story has not been edited by Mathrubhumi and is published from a syndicated feed.)
Published: 17 Nov 2026, 04:54 pm IST
Disclaimer: Kindly avoid objectionable, derogatory, unlawful and lewd comments, while responding to reports. Such comments are punishable under cyber laws. Please keep away from personal attacks. The opinions expressed here are the personal opinions of readers and not that of Mathrubhumi.